EGR3 was found to be significantly downregulated in tumor tissues compared with non-tumor tissues, such as nasopharyngeal carcinoma [12], prostate cancer [13], hepatocellular carcinoma [14], and epithelial ovarian cancer [15], which results in the poor prognosis and low survival of patients, thus suggesting that EGR3 could potentially serve as a biomarker in the diagnosis and prognosis assessment of cancer. The gene discussed is EGR3; the disease is prostate cancer.